IQVIA™ Real-World Insights Bibliography

Cardiovascular Effectiveness of Empagliflozin Compared to DPP-4i in Routine Care in East Asia: Results from the EMPRISE study
Author(s): Dae Jung Kim, Wayne H.-H. Sheu, Wook-Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Elise Chia-Hui Tan, Yusuke Taneda, Vanessa Lei, Laura Saarelainen, Anouk Deruaz-Luyet, Moe H. Kyaw, Yutaka Seino, EMPRISE East Asia Study Group, Boehringer Ingelheim International GmbH, Ingelheim, Germany, StatFinn - EPID Research an IQVIA Company, Espoo, Finland
Affiliations(s): 1 Ajou University, Suwon, South Korea; 2 Taichung Veterans General Hospital, Taichung, Taiwan; 3 Gachon University Gil Medical Center, Incheon, South Korea; 4 Kansai Electric Power Medical Research Institute, Kobe, Japan; 5 Gifu University Graduate School of Medicine, Gifu, Japan; 6 National Research Institute of Chinese Medicine, Taipei, Taiwan; 7 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; 8 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan; 9 IQVIA, Espoo, Finland; 10 Boehringer Ingelheim International GmbH, Ingelheim, Germany; 11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 12 Kansai Electric Power Hospital, Osaka, Japan
Publication(s):  J Am Coll Cardiol. 2021 May, 77 (18_Supplement_1) 542. https://doi.org/10.1016/S0735-1097(21)01901-X
Document Type(s): Abstract, Presentation,
Countries: Japan, South Korea, Taiwan,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes,
2021
  L:
A:
English
Database Study, Methodology, Observational study,
  Add to report
 
 
Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk ofcardiovascular and renal disease among type 2 diabetes patients in routinecare in europe and israel: EMPRISE study results
Author(s): T Nystroem1;AKarasik2; J Nunez3; S Lanzinger4; C Melzer-Cohen2; R W Holl4;P Casajust5; E Toresson Grip6; M Carrasco7; J Foersch8; K Karlsdotter9;M Tuovinen10; R Klement11;MHKyaw12; L Niskanen
Affiliations(s): Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Solna, Sweden;2Tel Aviv University, Maccabi Research and Innovation Center, Tel Aviv, Israel;3University of Valencia, Department of Cardiology, Hospital Clínico Universitariode Valencia, INCLIVA, CIBER Cardiovascular, Valencia, Spain;4University of Ulm,Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany;5Trial FormSupport, Real-World Evidence, Barcelona, Spain;6Swedish Institute for HealthEconomics Quantify Research, Stockholm, Sweden;7Boehringer Ingelheim EspañaS.A., Barcelona, Spain;8Boehringer Ingelheim Pharma GmbH & Co. Kg, HP CountryMedical Affairs, Ingelheim Am Rhein, Germany;9Boehringer Ingelheim AB, Stock-holm, Sweden;10Boehringer Ingelheim KY, Secondment Boehringer Ingelheim UKHEOR Team, Helsinki, Finland;11IQVIA, Global Database Studies, Tartu, Estonia;12Boehringer Ingelheim Pharmaceutical Inc., Connecticut, United States of America;13University of Eastern Finland, Kuopio, Finland;
Publication(s):  European Journal of Heart Failure (2021)23(Suppl. S2) 2?322doi:10.1002/ejhf.2297
Document Type(s): Abstract, Article,
Countries: Finland, Germany, Israel, Spain, Sweden,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes,
2021
  L:
A:
English
Database Study, Meta analysis, Methodology, Population Based Study,
  Add to report
 
 
Evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the Ninth Mount Hood Diabetes Challenge
Author(s): Si L, Willis MS, Asseburg C, Tew M, Clarke PM, Lamotte M, Ramos M, Hui S, Shi L, Zhang P, McEwan P, Ye W, Herman WH, Isaman DJ, Kuo S, Schramm W, Sailer F, Brennan A, Pollard D, Smolen HJ, Leal J, Gray A, Patel R, Feenstra T, Palmer AJ
Affiliations(s): IQVIA, Zaventem, Belgium and IQVIA, Lisbon, Portugal
Publication(s):  Value in Health
Document Type(s): Article,
Countries: UK,
C:
Y:
Diabetes,
2020
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Contrasting three type 2 diabetes cardiovascular risk equations for east asia with ukpds82 using the IQVIA core diabetes model
Author(s): Ramos M1, Monteiro S2, Olivieri AV3, Lamotte M1
Affiliations(s): 1 IQVIA, Zaventem, Belgium 2 IQVIA, London, UK 3 IQVIA, Basel, Switzerland
Publication(s):  ISPOR US 2020 Orlando, Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB56
Document Type(s): Article,
Countries: Asia Pacific,
C:
Y:
Diabetes,
2020
  L:
A:
English
Population Based Study,
  Add to report
 
 
Impact of using different types of hba1c progression in the IQVIA core diabetes model
Author(s): Ramos M1, Monteiro S2, Lamotte M1
Affiliations(s): 1 IQVIA, Zaventem, Belgium 2 IQVIA, London, UK
Publication(s):  ISPOR US 2020 Orlando Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB52
Document Type(s): Article,
Countries: UK,
C:
Y:
Diabetes,
2020
  L:
A:
English
Population Based Study,
  Add to report
 
 
Does including acute pancreatitis as a complication have an impact on cost-effectiveness analyses using the IQVIA core diabetes model?
Author(s): Monteiro S1, Ramos M2, Lamotte M2
Affiliations(s): 1 IQVIA, London, UK 2 IQVIA, Zaventem, Belgium
Publication(s):  ISPOR US 2020 Orlando Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB52
Document Type(s): Article,
Countries: UK,
C:
Y:
Diabetes,
2020
  L:
A:
English
Population Based Study,
  Add to report
 
 
Cost of Macrovascular Complications in People With Diabetes From a Public Healthcare Perspective: A Retrospective Database Study in Brazil
Author(s): Guilherme Silva Julian 1, Daniel Campos 1, Julie Broe Honore 2, Flávia Sauer Tobaruella 3, Jung Hyun Yoon 3, Nino Hallén 2
Affiliations(s): 1 IQVIA Brasil, São Paulo, Brazil. 2 Novo Nordisk A/S, Søborg, Denmark. 3 Novo Nordisk Farmacêutica Do Brasil Ltda, São Paulo, Brazil.
Publication(s):  PMID: 32372710 DOI: 10.1080/13696998.2020.1764966
Document Type(s): Article,
Countries: Brazil,
Click here for the abstract
C:
Y:
Diabetes,
2020
  L:
A:
English
Observational study, Retrospective database analysis,
  Add to report
 
 
Cross-sectional survey in patients with type 1 and type 2 diabetes to understand mealtime insulin unmet needs in Japan: The MINUTES-J study
Author(s): Hitoshi Ishii 1, Suzuki Shuichi 2, Paul Williams 3, Sven Demiya 4, Toshihiko Aranishi 2, Tamas Treuer 5 (rwesheorj 4)
Affiliations(s): 1) Department of Diabetology, Nara Medical University, Nara, Japan 2) Eli Lilly Japan, K.K., Kobe, Japan 3) RWE Patient-Centered Endpoints Center of Excellence, IQVIA, Paris, France 4) IQVIA Solutions K.K., Tokyo Japan 5) Eli Lilly and Company, Budapest, Hungary
Publication(s):  Diabetes Research and Clinical Practice
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Diabetes,
2020
  L:
A:
English
Patient questionnaire,
  Add to report
 
 
An Assessment of Physician Reasons for Prescribing Insulin Lispro 200 units/ml in Germany
Author(s): Jieling Chen1, Magaly Perez-Nieves1, Carolina Piras De Oliveira1, Erik Spaepen2, Beatrice Osumili3, Jiat Ling Poon1, Nanette Schloot2, Nuria Lara4, Laura Garcia Alvarez4, Montserrat Roset4
Affiliations(s): 1 Eli Lilly and Company, Indianapolis, US 2 Eli Lilly and Company, HaaPACS GmbH, Schriesheim, Germany 3 Eli Lilly and Company, Surrey, UK 4 IQVIA, Real World Solutions, Barcelona, Spain
Publication(s):  Postgraduate Medicine
Document Type(s): Article,
Countries: Germany,
Click here for the abstract
C:
Y:
Diabetes,
2020
  L:
A:
English
Compliance,
  Add to report
 
 
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
Author(s): Yutaka Seino*, Dae Jung Kim, Daisuke Yabe, Elise Chia-Hui Tan, Wook-Jin Chung, Kyoung Hwa Ha, Masaomi Nangaku, Koichi Node, Riho Klement**, Atsutaka Yasui, Wei-Yu, Sunwoo Lee, Moe H Kyaw, Anouk Deruaz-Luyet, Kimberly G Brodovicz,Wayne H-H Sheu, on behalf of the EMPRISE East Asia study group
Affiliations(s): * Kansai Electric Power Medical Research Institute, Kobe, Japan and Kansai Electric Power Hospital, Osaka, Japan **EPID Research an IQVIA company, Tartu, Estonia
Publication(s):  Endocrinology, Diabetes and Metabolism 2020;00:e00183
Document Type(s): Article,
Countries: Japan, South Korea, Taiwan,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes,
2020
  L:
A:
English
Epidemiological study, Retrospective database analysis,
  Add to report
 
 
First Page Previous Page  2 of 62 Next Page Last Page